









Markets
/
Stocks
/
nasdaq-idya
/

IDEAYA Biosciences Inc

IDYA



View Detailed Chart

35.200USD

-0.480-1.35%

Close 12/26, 16:00（ET）Quotes delayed by 15 min

3.09BMarket Cap

LossP/E TTM



IDEAYA Biosciences Inc

35.200

-0.480-1.35%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

-1.35%

5 Days

+5.83%

1 Month

-0.82%

6 Months

+59.93%

Year to Date

+36.96%

1 Year

+39.13%

View Detailed Chart

TradingKey Stock Score of IDEAYA Biosciences Inc

Currency: USD Updated: 2025-12-24

Key Insights

IDEAYA Biosciences Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 8/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 49.44.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

IDEAYA Biosciences Inc's Score

Industry at a Glance

Industry Ranking

8 / 404

Overall Ranking

47 / 4562

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 19 analysts

Buy

Current Rating

49.438

Target Price

+39.89%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

IDEAYA Biosciences Inc Highlights

StrengthsRisks

IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).

Growing

The company is in a growing phase, with the latest annual income totaling USD 7.00M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 7.00M.

Undervalued

The company’s latest PE is -18.81, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 105.73M shares, decreasing 9.87% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 76.99K shares of this stock.